(S)-1-(4-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)-1,2,5-thiadiazol-3-yl)pyrrolidin-2-one

ID: ALA5291230

Chembl Id: CHEMBL5291230

Max Phase: Preclinical

Molecular Formula: C19H23N5O3S

Molecular Weight: 401.49

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1CCCN1c1nsnc1N1CCN(C[C@H]2COc3ccccc3O2)CC1

Standard InChI:  InChI=1S/C19H23N5O3S/c25-17-6-3-7-24(17)19-18(20-28-21-19)23-10-8-22(9-11-23)12-14-13-26-15-4-1-2-5-16(15)27-14/h1-2,4-5,14H,3,6-13H2/t14-/m0/s1

Standard InChI Key:  JSQNCTPAQJYMNQ-AWEZNQCLSA-N

Alternative Forms

  1. Parent:

    ALA5291230

    ---

Associated Targets(Human)

ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 401.49Molecular Weight (Monoisotopic): 401.1522AlogP: 1.63#Rotatable Bonds: 4
Polar Surface Area: 71.03Molecular Species: NEUTRALHBA: 8HBD:
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 6.26CX LogP: 2.20CX LogD: 2.17
Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.77Np Likeness Score: -1.14

References

1. Wang S, Haikarainen A, Pohjakallio A, Sipilä J, Kaskinoro J, Juhila S, Jalava N, Koskinen M, Vesajoki M, Kumpulainen E, Pystynen J, Koskelainen T, Holm P, Din Belle D..  (2022)  Development of benzodioxine-heteroarylpiperazines as highly potent and selective α2c antagonists.,  77  [PMID:36174834] [10.1016/j.bmcl.2022.129005]

Source